A Randomized, Multicenter, Double-Blind, Non-inferiority Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Subjects With Schizophrenia

Trial Profile

A Randomized, Multicenter, Double-Blind, Non-inferiority Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Subjects With Schizophrenia

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Jul 2016

At a glance

  • Drugs Paliperidone (Primary)
  • Indications Schizophrenia
  • Focus Registrational; Therapeutic Use
  • Sponsors Janssen Research & Development; Janssen-Cilag
  • Most Recent Events

    • 27 Jun 2016 According to Janssen media release, Health Canada has approved INVEGA TRINZA™ (paliperidone palmitate), an antipsychotic medication for schizophrenia.
    • 22 Jun 2016 Results assessing Phase III dose selection based on the data from a 6-month interim analysis of other trial (see profile 215279) published in the British Journal of Clinical Pharmacology
    • 31 May 2016 According to a Janssen-Cilag media release, the European Commission has approved TREVICTA for the maintenance treatment of schizophrenia in adults based on results from this and another phase III trial (CTP 700213328).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top